Abstract 2126P
Background
The beneficial effects of exercise for cancer patients are well recognized but implemented exercise programs remain scarce, especially for patients during medical treatment. For that reason, we developed a supervised, personalized exercise concept for cancer patients, implemented into a clinical, oncological setting.
Methods
Cancer patients before, during or eventually after their medical treatment with an identified need for exercise could participate in a free of charge exercise intervention for at least three months at the University Hospital Cologne, Germany. We recorded demographic and medical data at enrolment and exercise adherence up to one year.
Results
A sample of n=1.660 patients attended the exercise program. The majority of patients were female (70%), under medical treatment (65%), diagnosed with breast cancer (40%), without metastasis or severe comorbidities (>70%) and on average 54 years old. The median time between diagnosis and exercise participation differed in patients during medical treatment (4 months), patients with metastasis (7 months) and cancer survivors (11 months). Almost one third (31%) discontinued exercise within the first two weeks of participation. Prolonged exercise (median: 19 weeks) was achieved by one third (32%) of the patients. The average exercise adherence was ∼1 session a week with <3% of patients reaching ≥2 sessions a week
Conclusions
To our knowledge, this is the worlds-first report of a professional, supervised exercise program tailored for cancer patients under medical treatment implemented into a clinical setting with >1.600 patients. We described the population that was referred to an exercise program, identified barriers to exercise participation and observed an important mismatch between recommendations and real-world exercise data. Exercise participation was engaged ≥4months after diagnosis and only a third of the patients exercised longer than three months. Almost all patients undercut the well-established exercise recommendations of ≥2 sessions a week. Future implementation concepts should optimize exercise initiation timely after diagnosis and adherence levels due to innovative exercise approaches.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University Hospital of Cologne, Cologne, Germany.
Funding
German Cancer Aid.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2105P - Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in breast cancer patients: A pilot application study
Presenter: Rita De Sanctis
Session: Poster session 06
2106P - Safety and patient reported outcomes of SARS-CoV-2 vaccination in patients with cancer
Presenter: Amy Body
Session: Poster session 06
2107P - Thromboprophylaxis with intermediate or prophylactic doses of LMWHs in ambulatory cancer patients
Presenter: Nikolaos Tsoukalas
Session: Poster session 06
2108P - Vitamin B12 and its clinical relevance in hospitalized cancer patients
Presenter: Stefano Maccarone
Session: Poster session 06
2109P - Vitamin A, D and E levels in patients with solid tumors undergoing palliative systemic cancer treatment
Presenter: Julia Berger
Session: Poster session 06
2111P - The value of multiple psychometric tools for distress screening and referral in a cancer population
Presenter: Daniel Anderson
Session: Poster session 06
2112P - Initial geriatric assessment and chemotherapy tolerability treatment in Brazilian patients with malignant neoplasm of the digestive system
Presenter: Marcos Dumont Bonfin Santos
Session: Poster session 06
2113P - Efficacy and effectiveness of prophylactic magnesium supplementation on prevention of cisplatin-induced nephrotoxicity: A systematic review and meta-analysis
Presenter: Caio Castro
Session: Poster session 06
2114P - Impact of comprehensive geriatric assessment (CGA) in the management of chemotherapy toxicity in older cancer patients
Presenter: Jordi Recuero-Borau
Session: Poster session 06